Is Integra LifeSciences Holdings Corp. overvalued or undervalued?

As of 4 November 2024, the valuation grade for Integra LifeSciences Holdings Corp. has moved from expensive to risky. The company appears to be overvalued given its current metrics, including a P/E ratio of 10, a Price to Book Value of 0.73, and an EV to EBITDA of 9.20. In comparison, peers such as Globus Medical, Inc. have a P/E of 18.37 and Sanmina Corp. boasts a P/E of 39.80, indicating that Integra is lagging behind its competitors in terms of valuation.
Furthermore, Integra's recent stock performance has been disappointing, with a year-to-date return of -32.19%, significantly underperforming the S&P 500's return of 12.22% in the same period. This underperformance, coupled with the company's risky valuation grade, reinforces the conclusion that Integra LifeSciences is currently overvalued.